147 related articles for article (PubMed ID: 10957771)
1. [From antigen to tumor marker. Results of research regarding PSA and its clinical applications].
De Angelis G; Brandt B; Schmid HP; Semjonow A
Urologe A; 2000 Jul; 39(4):309-12. PubMed ID: 10957771
[TBL] [Abstract][Full Text] [Related]
2. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
Haese A; Graefen M; Palisaar J; Huland E; Huland H
Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750
[TBL] [Abstract][Full Text] [Related]
3. PSA as a treatment marker for prostate cancer?
Miller M
J Natl Cancer Inst; 1999 Jul; 91(13):1108-10. PubMed ID: 10393715
[No Abstract] [Full Text] [Related]
4. Prostate specific antigen through the years.
Kouriefs C; Sahoyl M; Grange P; Muir G
Arch Ital Urol Androl; 2009 Dec; 81(4):195-8. PubMed ID: 20608139
[TBL] [Abstract][Full Text] [Related]
5. [PSA-based early detection of prostate cancer].
Luboldt H; Rübben H
Urologe A; 2000 Jan; 39(1):22-6. PubMed ID: 10663192
[TBL] [Abstract][Full Text] [Related]
6. The value of prostatic specific antigen density in the early diagnosis of prostate cancer.
Deliveliotis Ch; Louras G; Kyriazis P; Gyftopoulos A; Louka L; Alargof E
Int Urol Nephrol; 1998; 30(3):305-10. PubMed ID: 9696337
[TBL] [Abstract][Full Text] [Related]
7. [German Cancer Society e.V. S3 guideline for PSA determination in diagnosis of prostatic carcinoma].
Rübben H; Schalkhäuser K; Wolff J; Luboldt HJ;
Onkologie; 2003 Feb; 26(1):88-9. PubMed ID: 12661558
[No Abstract] [Full Text] [Related]
8. [Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis].
Lein M; Stephan C; Jung K; Schnorr D; Loening SA
Urologe A; 2000 Jul; 39(4):313-23. PubMed ID: 10957772
[TBL] [Abstract][Full Text] [Related]
9. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
10. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
[TBL] [Abstract][Full Text] [Related]
11. [Significance of the PSA-concentration for the detection of prostate cancer].
Stachon A
Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
[TBL] [Abstract][Full Text] [Related]
12. [PSA 2010--the beginning of a new era in early detection of prostate cancer].
Börgermann C; Sieverding M; Fornara P; Graefen M; Hammerer P; Semjonow A; Schröder F; Rübben H
Urologe A; 2006 Sep; 45 Suppl 4():127-33. PubMed ID: 16941115
[No Abstract] [Full Text] [Related]
13. Prostatic specific antigen (PSA).
Alberti C
Minerva Urol Nefrol; 1993 Jun; 45(2):83-4. PubMed ID: 7694380
[No Abstract] [Full Text] [Related]
14. [Early detection of prostatic carcinoma in urologic practice with digital rectal examination and prostate-specific antigen. Early Detection Project Group].
Luboldt HJ; Hüsing J; Altwein JE; Bichler KH; Czaja D; Fornara P; Jöckel KH; Schalkhäuser K; Weissbach L; Wirth M; Rübben H
Urologe A; 2000 Jul; 39(4):330-3. PubMed ID: 10957774
[TBL] [Abstract][Full Text] [Related]
15. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications.
Shinohara K; Wolf JS; Narayan P; Carroll PR
J Urol; 1994 Jul; 152(1):120-3. PubMed ID: 7515447
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen and prostatic acid phosphatase in the detection of early prostate cancer and in the prediction of regional lymph node metastases.
Wirth MP; Frohmüller HG
Eur Urol; 1992; 21(4):263-8. PubMed ID: 1281102
[TBL] [Abstract][Full Text] [Related]
17. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density.
Wolff JM; Scholz A; Boeckmann W; Jakse G
Eur Urol; 1994; 25(4):295-8; discussion 304. PubMed ID: 7519991
[TBL] [Abstract][Full Text] [Related]
19. [Status of PSA determination for early detection of prostate carcinoma].
Hammerer P; Huland H
Versicherungsmedizin; 1995 Jun; 47(3):83-6. PubMed ID: 7541925
[TBL] [Abstract][Full Text] [Related]
20. PSA screening for prostate cancer: the current controversy.
de Koning HJ; Schröder FH
Ann Oncol; 1998 Dec; 9(12):1293-6. PubMed ID: 9932158
[No Abstract] [Full Text] [Related]
[Next] [New Search]
